Trial
NCT02241720
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
—
Condition
Upper GI Cancer
Intervention
regorafenib
Why stopped
Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-11